PMID- 36169731 OWN - NLM STAT- MEDLINE DCOM- 20221206 LR - 20221206 IS - 1433-7339 (Electronic) IS - 0941-4355 (Print) IS - 0941-4355 (Linking) VI - 30 IP - 12 DP - 2022 Dec TI - mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. PG - 9687-9690 LID - 10.1007/s00520-022-07376-w [doi] AB - PURPOSE: This study aims to describe the incidence and severity of adverse events (AEs) following the mRNA-1273 SARS-CoV-2 vaccine and explore the risk perception of COVID-19 in allogeneic hematopoietic stem cell transplant (HCT) recipients. METHODS: We performed a single-center prospective study including recently transplanted (< 2 years post-infusion) allogeneic HCT recipients. AEs were assessed through phone calls and graded from 0 to 4, while COVID-19 risk perception was measured using the Brief Illness Perception Questionnaire (BIP-Q5). RESULTS: Fifty-four HCT recipients were evaluated. Incidence and grades of AE (94.4% and 85.2% after the first and second dose, respectively) were similar to those described in the general population. The most common AE was pain at the site of injection. Three patients (5.6%) developed a grade >/= 3 AE. Vaccine-related cytopenias and graft-versus-host disease flares were not observed. Female sex (OR 3.94, 95% CI 1.14-13.58, p = 0.03) and time since HCT (per month since HCT: OR 1.09, 95% CI 1.01-1.18, p = 0.04) were associated with the occurrence of any AE. The patients' risk perception level of COVID-19 decreased over time (p < 0.05). CONCLUSION: Our study confirms that the mRNA-1273 SARS-CoV-2 vaccine is safe in recent HCT recipients and suggests that the perceived risk of COVID-19 decreases over time. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Albiol, Nil AU - Albiol N AUID- ORCID: 0000-0003-2942-1362 AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. nilalbiol@iconcologia.net. AD - Institut d'Investigacio Biomedica (IIB) Sant Pau, Barcelona, Spain. nilalbiol@iconcologia.net. AD - Autonomous University of Barcelona, Barcelona, Spain. nilalbiol@iconcologia.net. AD - Josep Carreras Leukaemia Research Institute, Barcelona, Spain. nilalbiol@iconcologia.net. FAU - Aso, Olga AU - Aso O AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Gomez-Perez, Lucia AU - Gomez-Perez L AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Triquell, Merce AU - Triquell M AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Roch, Nerea AU - Roch N AD - Infectious Diseases Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Lazaro, Elisabeth AU - Lazaro E AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Esquirol, Albert AU - Esquirol A AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. AD - Institut d'Investigacio Biomedica (IIB) Sant Pau, Barcelona, Spain. AD - Autonomous University of Barcelona, Barcelona, Spain. AD - Josep Carreras Leukaemia Research Institute, Barcelona, Spain. FAU - Gonzalez, Iria AU - Gonzalez I AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Lopez-Contreras, Joaquin AU - Lopez-Contreras J AD - Autonomous University of Barcelona, Barcelona, Spain. AD - Infectious Diseases Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. FAU - Sierra, Jorge AU - Sierra J AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. AD - Institut d'Investigacio Biomedica (IIB) Sant Pau, Barcelona, Spain. AD - Autonomous University of Barcelona, Barcelona, Spain. AD - Josep Carreras Leukaemia Research Institute, Barcelona, Spain. FAU - Martino, Rodrigo AU - Martino R AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. AD - Institut d'Investigacio Biomedica (IIB) Sant Pau, Barcelona, Spain. AD - Autonomous University of Barcelona, Barcelona, Spain. AD - Josep Carreras Leukaemia Research Institute, Barcelona, Spain. FAU - Garcia-Cadenas, Irene AU - Garcia-Cadenas I AUID- ORCID: 0000-0002-2994-9055 AD - Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain. igarciaca@santpau.cat. AD - Institut d'Investigacio Biomedica (IIB) Sant Pau, Barcelona, Spain. igarciaca@santpau.cat. AD - Autonomous University of Barcelona, Barcelona, Spain. igarciaca@santpau.cat. AD - Josep Carreras Leukaemia Research Institute, Barcelona, Spain. igarciaca@santpau.cat. LA - eng GR - 517C/20190318/1330/Fundacio la Marato de TV3/ GR - FIS PI17/01246/Instituto de Salud Carlos III/ GR - AGAUR 2017 SGR 865/Instituto de Salud Carlos III/ GR - Tercel RD16/0011/0028/Instituto de Salud Carlos III/ PT - Journal Article DEP - 20220928 PL - Germany TA - Support Care Cancer JT - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JID - 9302957 RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) SB - IM EIN - Support Care Cancer. 2022 Nov 19;:. PMID: 36400980 MH - Female MH - Humans MH - *2019-nCoV Vaccine mRNA-1273/adverse effects/therapeutic use MH - *COVID-19/prevention & control MH - *Hematopoietic Stem Cell Transplantation MH - Prospective Studies MH - SARS-CoV-2 MH - Transplantation, Homologous MH - Health Knowledge, Attitudes, Practice MH - Surveys and Questionnaires PMC - PMC9517991 OTO - NOTNLM OT - Adverse events OT - Allogeneic stem cell transplantation OT - COVID-19 OT - Risk perception OT - mRNA-1273 COIS- AB: Stocks in Grifols, Almirall. Other authors declare no competing financial interests. EDAT- 2022/09/29 06:00 MHDA- 2022/12/06 06:00 PMCR- 2022/09/28 CRDT- 2022/09/28 11:16 PHST- 2022/01/25 00:00 [received] PHST- 2022/09/21 00:00 [accepted] PHST- 2022/09/29 06:00 [pubmed] PHST- 2022/12/06 06:00 [medline] PHST- 2022/09/28 11:16 [entrez] PHST- 2022/09/28 00:00 [pmc-release] AID - 10.1007/s00520-022-07376-w [pii] AID - 7376 [pii] AID - 10.1007/s00520-022-07376-w [doi] PST - ppublish SO - Support Care Cancer. 2022 Dec;30(12):9687-9690. doi: 10.1007/s00520-022-07376-w. Epub 2022 Sep 28.